[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zealand Pharma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":153},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,83,105,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100648450","early-phase-1-a-single-and-multiple-ascending-dose-trial-assessing-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-zp6590-in-participants-with-normal-weight-overweight-and-obesity-100648450",false,"NCT07721597","A Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity","A First-in-human, Randomized, Single and Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP6590 in Participants With Normal Weight, Overweight and Obesity","Inclusion Criteria:\n\nSAD-Part:\n\n* Male participant\n* Age between 18 and 55 years, both inclusive\n* Body Mass Index (BMI) between 20.0 and 29.9 kg\u002Fm\\^2, both inclusive\n\nMAD-Part:\n\n* Male participant\n* Age between 18 and 60 years, both inclusive\n* Body Mass Index (BMI) between 27.0 and 39.9 kg\u002Fm\\^2, both inclusive\n\nExclusion Criteria:\n\nSAD-Part and MAD-Part:\n\n* Any clinically significant abnormal haematology, biochemistry, or urinalysis screening tests, as judged by the investigator\n* Treatment for weight management within 3 months before randomization in this trial",true,"MALE","18 Years","60 Years",{"count":21,"type":22},88,"ESTIMATED","INTERVENTIONAL",[25],"EARLY_PHASE1","The goal of this clinical trial is to learn about the safety and tolerability of drug ZP6590 and to learn how the body processes the drug ZP6590 in adults. The main questions it aims to answer are:\n\n* Is the drug ZP6590 safe and well tolerated when administered as escalating single and multiple doses of the ZP6590?\n* How quickly and to what extent the administered investigational drug is absorbed and distributed, and how long it takes to be eliminated from the body?\n\nIn the first Part of the study:\n\nParticipants will:\n\n• Get a single ascending dose of the drug ZP6590 or placebo and will have an observation period of 4 weeks.\n\nIn the second Part of the study:\n\nParticipants will:\n\n• Get multiple dosages of the drug ZP6590 or placebo for 6 or 12 weeks followed by an observation period of 6 weeks after last dosing.",[28,29,30],"Healthy Participants Study","Overweight and Obese Adults","First in Man Study to Evaluate Initial Safety",[32,33,34,35],"ZP6590","Safety and Tolerability","GIP-R agonist","obesity","RECRUITING","2026-08-12",{"date":39,"type":40},"2026-08-13","ACTUAL",{"date":42,"type":40},"2026-07-09",{"date":44,"type":22},"2027-09-06",{"name":46,"class":47},"Zealand Pharma","INDUSTRY",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":18,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100608160","phase-3-efficacy-and-safety-evaluation-of-glepaglutide-in-treatment-of-sbs-100608160","NCT07197944","Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS","A Phase 3, Double-blind, Randomized, Parallel Group, Placebo-controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice Weekly, Followed by a Long-term, Open-label Safety Evaluation in Patients With Short Bowel Syndrome-intestinal Failure (SBS-IF)","EASE SBS 5","Key Inclusion Criteria:\n\n* Signed informed consent;\n* Age of 18 to 90 years;\n* A diagnosis of SBS, defined as having a small bowel with an estimated length of less than 200 cm (equal to 79 inches) in continuity (latest intestinal resection ≥6 months before screening);\n* Stable PS need of ≥3 days per week;\n* No restorative surgery planned during the trial period;\n* Having a stoma or colon in continuity.\n\nKey Exclusion Criteria:\n\n* More than 2 SBS- or PS-related hospitalizations within 6 months before screening;\n* Poorly controlled Inflammatory Bowel Disease (IBD) that is moderately or severely active or a fistula that can interfere with the measurements or examinations required in the trial;\n* History of colorectal cancer or any other type of cancer (except for margin-free resected cutaneous basal, squamous cell carcinoma or adequately treated in situ cervical cancer) unless the patient has been disease-free for at least 5 years; ongoing bowel obstruction;\n* BMI \\\u003C18.5 kg\u002Fm\\^2.","ALL","90 Years",{"count":60,"type":22},90,[62],"PHASE3","The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data.\n\nGlepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.",[65],"Short Bowel Syndrome",[67,68,69,70,71,72,73,65,74],"Intestinal Failure","Pathologic Processes","Malabsorption Syndromes","Intestinal Diseases","Gastrointestinal Diseases","Digestive System Diseases","Postoperative Complications","Syndrome","2026-08-11",{"date":37,"type":40},{"date":78,"type":40},"2026-02-11",{"date":80,"type":22},"2032-02-28",{"name":46,"class":47},31,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":57,"minAge":18,"maxAge":19,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":48},"100649434","phase-1-a-trial-to-understand-how-safe-and-well-tolerated-zp9830-is-and-how-it-works-in-people-with-plaque-psoriasis-over-an-8-week-treatment-period-100649434","NCT07733089","A Trial to Understand How Safe and Well Tolerated ZP9830 is and How it Works in People With Plaque Psoriasis Over an 8-week Treatment Period","An Interventional, Randomized, Double-blind, Placebo-controlled, Multiple Dose Trial Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Clinical Efficacy of ZP9830 Administered for 8 Weeks in Participants With Plaque Psoriasis","Inclusion Criteria:\n\n* Participants with a confirmed diagnosis of psoriasis (stable plaque psoriasis ≥ 2 months).\n* Participants who have ≥ 2 vulgar psoriatic plaques.\n* BMI within the range 18.0-35.0 kg\u002Fm2 (inclusive).\n* Further inclusion criteria apply.\n\nExclusion Criteria:\n\n* Erythrodermic, predominantly guttate, exclusively palmar\u002Fplantar, or generalized pustular psoriasis.\n* Current drug-induced or aggravated psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta-blockers, calcium-channel blockers, or lithium carbonate).\n* Any clinically significant abnormalities, as judged by the investigator, in laboratory test results (including hematology, biochemistry, and urinalysis).\n* Any clinically significant abnormal findings during the standardized neurological examination conducted at screening.\n* Use of any concurrent systemic medications that could affect psoriasis or psoriasis evaluation, including corticosteroids, retinoids, cyclosporine, methotrexate, PDE4s (phosphodiesterase 4), or biologic agents within 30 days prior to IMP administration or planned to use during the course of the trial.\n* Use of concurrent topical medications containing corticosteroids, retinoids, calcitriol or other topical medication relevant to psoriasis treatment (must be discontinued at least 2 weeks prior to baseline).\n* Use of any biologic or advance systemic therapies for any autoimmune disease within the last 12 months.\n* Use of UVA, PUVA, or UVB therapy and tanning beds within 4 weeks of baseline or during trial participation.\n* Further exclusion criteria apply.",{"count":91,"type":22},32,[93],"PHASE1","The purpose of this trial is to investigate the effects of repeated administration of ZP9830 for 8 weeks in participants with plaque psoriasis. Here, the primary aim is to evaluate safety and tolerability of ZP9830, the secondary aims are to test clinical efficacy and pharmacokinetics, and lastly the exploratory aim is to test the pharmacodynamic effects of ZP9830 treatment.",[96],"Plaque Psoriasis","2026-07-28",{"date":99,"type":40},"2026-07-29",{"date":101,"type":40},"2026-07-22",{"date":103,"type":22},"2027-04",{"name":46,"class":47},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":16,"sex":57,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},"100646928","phase-1-pharmacokinetics-of-petrelintide-in-participants-with-impaired-hepatic-function-100646928","NCT07682818","Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function","Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Hepatic Function","Inclusion Criteria:\n\nAll participants:\n\n1. Sex: male and female participants.\n2. Body mass index (BMI): 18.5 to 40.0 kg\u002Fm\\^2, inclusive, at screening.\n\n   Additional Inclusion Criteria for Participants with Normal Hepatic Function\n3. Participants who are considered healthy as determined by medical history, physical examination, and other screening procedures, with clinically normal hepatic function at screening..\n4. Clinical laboratory test results within normal reference range for the population, or results with acceptable deviations that are judged not to be clinically significant by the Investigator.\n\n   Additional Inclusion Criteria for Participants with Hepatic Impairment\n5. Participants with stable HI for at least 3 months, classified as Child-Pugh Grade A, B, or C as assessed by the Investigator.\n6. Participants should be otherwise judged to be in acceptable health (type 2 diabetes mellitus \\[T2DM\\] is allowed) in the opinion of the Investigator based on a medical evaluation (including a physical examination, medical history, electrocardiogram \\[ECG\\], vital signs, concomitant medication and the results of laboratory safety tests) performed during the screening visit.\n7. Participants with T2DM may be enrolled if they have\u002Fare: a. Hemoglobin A1c ≤11% at screening b. On a stable regimen for at least 8 weeks prior to screening, defined as: stable diet and exercise program, and\u002For, stable dose of metformin, and\u002For, stable dose of a sodium-glucose cotransporter-2 inhibitor.\n\nExclusion Criteria:\n\nAll participants:\n\n1. Known or suspected hypersensitivity to the IMP or related products.\n2. Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using a highly effective contraceptive method.","70 Years",{"count":114,"type":22},36,[93],"This clinical research trial is testing the investigational medicinal product (IMP) petrelintide that is being developed for body weight reduction in people living with obesity or overweight who have comorbidities.\n\nThe aim of this clinical research trial is to investigate whether the pharmacokinetics (PK) of petrelintide will be different in people with hepatic impairment (HI) compared to people with normal hepatic function.",[118],"Impaired Hepatic Function",[120,118,121],"HI","Petrelintide","2026-06-26",{"date":124,"type":40},"2026-07-06",{"date":126,"type":40},"2026-05-18",{"date":128,"type":22},"2027-04-12",{"name":46,"class":47},3,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":16,"sex":57,"minAge":18,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":48},"100568572","phase-1-a-research-study-looking-at-the-safety-of-single-and-multiple-doses-of-zp9830-and-how-it-works-in-the-body-of-healthy-participants-100568572","NCT06682975","A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy Participants","A First-in-human, Randomized and Double-blind Within Cohorts, Placebo-controlled, Single and Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP9830 Administered to Healthy Participants.","Inclusion Criteria:\n\n* Healthy participants.\n* 18-45 years of age (inclusive).\n* Body weight ≥50 kg.\n* SAD part B only: Fitzpatrick skin type I-III (Caucasian).\n* C-reactive protein ≤10 mg\u002FL.\n* Further inclusion criteria apply.\n\nExclusion Criteria:\n\n* Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of it might interfere with, the conduct or the interpretation of the results of the trial, or that would pose an unacceptable risk to the subject in the opinion of the Investigator \\[following a detailed medical history, physical examination, vital signs (systolic and diastolic blood pressure, pulse rate, body temperature) and 12-lead ECG\\].\n* Any disease associated with immune system impairment, including immune mediated diseases and transplantation patients.\n* Any confirmed significant allergic reactions (urticaria or anaphylaxis) to insect bites.\n* History of neurological disorders including neuropathy, as judged by the investigator.\n* Any confirmed significant allergic reactions (urticaria or anaphylaxis) against any drug or food (in particular any level of severity of allergy to shellfish), or multiple drug allergies (non-active hay fever is acceptable).\n* Further exclusion criteria apply.","45 Years",{"count":140,"type":22},124,[93],"The primary object in this research study is to investigate the safety and tolerability of ZP9830 in healthy study participants, and in addition, the study will investigate how ZP9830 works in the body (pharmacokinetics, PK and pharmacodynamics, PD) compared to placebo.",[144],"Healthy Volunteers","2026-02-12",{"date":147,"type":40},"2026-02-17",{"date":149,"type":40},"2024-11-12",{"date":151,"type":22},"2026-08",{"name":46,"class":47},""]